everi
year
emerg
reemerg
virus
ebola
viru
ebov
marburg
viru
marv
rift
valley
fever
viru
rvfv
surfac
natur
reservoir
kill
peopl
addit
influenza
viru
fluav
human
immunodefici
herp
simplex
hsv
virus
regularli
infect
human
popul
repres
substanti
public
health
econom
burden
world
health
organ
unit
nation
un
call
better
control
viral
diseas
http
wwwwhointblueprintprioritydiseasesen
http
sustainabledevelopmentunorg
develop
novel
virusspecif
vaccin
antivir
drug
timeconsum
costli
order
overcom
time
cost
issu
academ
institut
pharmaceut
compani
focus
reposit
exist
antivir
one
viral
diseas
anoth
consid
mani
virus
util
host
factor
pathway
replic
insid
cell
broadspectrum
antivir
agent
bsaa
smallmolecul
inhibit
wide
rang
human
virus
recent
review
approv
investig
experiment
antivir
compound
identifi
bsaa
whose
pharmacokinet
pk
toxic
studi
clinic
trial
test
bsaa
human
metapneumoviru
hmpv
hepat
c
viru
hcv
cytomegaloviru
cmv
hepat
b
viru
hbv
demonstr
novel
antivir
effect
azacytidin
itraconazol
lopinavir
nitazoxanid
oritavancin
hmpv
well
cidofovir
dibucain
azithromycin
gefitinib
minocyclin
oritavancin
pirlindol
hcv
also
test
bsaa
includ
fluav
rvfv
echoviru
zikv
chikv
rrv
identifi
novel
activ
dalbavancin
ezetimib
zikv
azacytidin
cyclosporin
minocyclin
oritavancin
ritonavir
rvfv
evalu
efficaci
bsaa
overlap
agent
test
identifi
novel
vitro
activ
obatoclax
emetin
hmpv
rvfv
moreov
demonstr
novel
antivir
effect
emetin
fluav
niclosamid
brequinar
homoharringtonin
vitro
identifi
potenti
bsaa
review
approv
investig
safeinman
antivir
agent
use
drug
bank
clinic
trial
websit
respect
addit
review
investig
approv
safeinman
antibacteri
antifung
antiprotozo
antiemet
etc
agent
antivir
activ
report
pubm
exclud
vaccin
interferon
identifi
molecul
inhibit
replic
sever
virus
man
recent
novel
antivir
activ
report
agent
fortythre
compound
use
studi
supplier
catalogu
number
summar
tabl
obtain
mm
stock
solut
compound
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
steinheim
germani
milliq
water
solut
store
use
canin
kidney
mdck
american
type
cultur
collect
atcc
african
green
monkey
kidney
epitheli
atcc
cell
grown
dulbecco
modifi
eagl
medium
dmem
gibco
paisley
scotland
supplement
uml
penicillin
streptomycin
mixtur
penstrep
lonza
cologn
germani
mm
lglutamin
heatinactiv
fetal
bovin
serum
fb
lonza
cologn
germani
human
telomeras
revers
transcriptaseimmort
retin
pigment
epitheli
rpe
atcc
cell
grown
medium
supplement
penstrep
mm
lglutamin
fb
sodium
bicarbon
sigmaaldrich
st
loui
usa
cell
possess
singl
integr
copi
proviru
strain
lai
nih
aid
reagent
program
grown
medium
supplement
fb
penstrep
tzmbl
cell
grown
dmem
supplement
fb
penstrep
human
lung
adenocarcinoma
epitheli
cell
cultur
dmem
medium
contain
fb
penstrep
cell
kindli
provid
prof
steve
goodbourn
univers
london
stabli
express
bvdv
npro
protein
inhibit
ifn
product
cultur
dmem
contain
fb
penstrep
puromycin
cell
line
grown
humidifi
incub
presenc
strain
g
atcc
farouk
strain
atcc
prof
univers
rvfv
encod
far
fluoresc
protein
instead
nonstructur
ns
protein
rvfvrfp
prof
hartmut
hengel
friedemann
weber
univers
medic
center
freiburg
hmpv
strain
encod
green
fluoresc
protein
hmpvgfp
vironov
erasmu
mc
gfpexpress
influenza
strain
fluavgfp
gener
dr
andrej
egorov
vienna
experi
virus
perform
complianc
guidelin
nation
author
use
appropri
biosafeti
laboratori
appropri
ethic
safeti
approv
fluavgfp
amplifi
monolay
mdck
cell
dmem
contain
penstrep
bovin
serum
albumin
mm
lglutamin
chloromethyl
ketonetrypsin
tpck
trypsin
sigmaaldrich
st
loui
usa
hmpvgfp
rvfvrfp
wildtyp
strain
amplifi
monolay
cell
dmem
medium
contain
penstrep
bovin
serum
albumin
mm
lglutamin
tpcktrypsin
amplifi
monolay
cell
dmem
media
contain
penstrep
bovin
serum
albumin
mm
lglutamin
product
cell
seed
ml
medium
viru
product
induc
addit
nm
cell
incub
h
medium
collect
concentr
estim
measur
concentr
medium
use
develop
inhous
recombin
purifi
protein
use
refer
viru
stock
store
approxim
rpe
cell
seed
per
well
plate
cell
grown
h
medium
supplement
fb
penstrep
medium
replac
medium
contain
bovin
serum
albumin
mm
lglutamin
tpsktrypsin
compound
ad
cell
dilut
seven
differ
concentr
start
saliphenylhalamid
dmso
ad
control
well
saliphenylhalamid
inhibitor
cellular
vacuolar
atpas
protect
cell
virusmedi
death
wherea
inhibitor
antiapoptot
protein
facilit
death
cell
viral
nucleic
acid
rpe
cell
infect
fluavgfp
hmpvgfp
rvfvrfp
virus
multipl
infect
moi
respect
rpe
cell
imag
h
phasecontrast
mode
rvfvmediat
rfp
express
fluavmedi
gfp
express
visual
h
wherea
hmpvmediat
gfp
express
record
h
use
fluoresc
microscopi
zeiss
observ
zaventem
belgium
imag
j
softwar
vij
nih
use
determin
fluoresc
intens
rpe
cell
treat
bsaa
control
compound
describ
infect
fluavgfp
hmpvgfp
rvfvrfp
virus
multipl
infect
moi
respect
h
infect
medium
remov
cell
viabil
mock
virusinfect
cell
measur
use
cell
titer
glow
assay
ctg
promega
madison
usa
luminescencefluoresc
read
pherastar
fs
plate
reader
bmg
labtech
ortenberg
germani
test
compound
toxic
efficaci
approxim
tzmbl
cell
seed
well
plate
tzmbl
cell
express
firefli
luciferas
control
long
termin
repeat
ltr
promot
allow
quantit
viral
infect
tatprotein
express
integr
proviru
use
firefli
luciferas
assay
cell
grown
h
cell
growth
medium
compound
ad
cell
threefold
dilut
seven
differ
concentr
start
compound
ad
control
well
cell
infect
correspond
ngml
mock
hpi
media
remov
cell
cell
lyse
firefli
luciferas
activ
measur
use
luciferas
assay
system
promega
madison
wi
usa
pherastar
fs
plate
reader
parallel
experi
cell
tox
green
reagent
ctxg
promega
madison
wi
usa
ad
cell
fluoresc
measur
plate
reader
halfmaxim
cytotox
concentr
compound
calcul
base
viabilitydeath
curv
obtain
mockinfect
cell
nonlinear
regress
analysi
variabl
slope
use
graphpad
prism
softwar
version
halfmaxim
effect
concentr
calcul
base
analysi
report
protein
express
viabilitydeath
infect
cell
fit
drug
curv
use
fourparamet
logist
function
f
x
f
x
respons
valu
dose
x
amin
amax
upper
lower
asymptot
minim
maxim
drug
effect
dose
produc
halfmaxim
effect
steep
slope
curv
rel
effect
drug
defin
select
index
si
threshold
si
use
differenti
activ
inact
compound
rpe
cell
treat
combin
increas
concentr
obatoclax
emetin
cell
infect
fluavgfp
moi
h
gfp
fluoresc
record
use
fluoresc
microscopi
parallel
experi
viabil
infect
cell
measur
use
ctg
assay
test
whether
drug
combin
act
synergist
observ
respons
compar
expect
combin
respons
expect
respons
emetineobatoclax
drug
combin
viabil
fluav
mockinfect
rpe
cell
calcul
use
bliss
refer
model
test
product
virus
compoundtr
nontreat
rpe
cell
media
cell
serial
dilut
start
serumfre
growth
media
contain
bovin
serum
albumin
appli
monolay
cell
plate
one
hour
cell
overlaid
growth
medium
contain
carboxymethyl
cellulos
fb
incub
h
cell
fix
stain
crystal
violet
dye
plaqu
calcul
well
titer
express
plaqueform
unit
per
ml
pfuml
fortythre
safeinman
bsaa
use
studi
reach
differ
stage
drug
develop
process
figur
tabl
altogeth
bsaa
inhibit
replic
virus
belong
singlestrand
ss
rna
ssrna
ssrnarevers
transcriptas
rt
ssdna
doublestrand
ds
dna
dsdnart
viru
group
test
bsaa
wildtyp
rpe
cell
seven
differ
concentr
compound
ad
viru
mockinfect
cell
cell
viabil
monitor
microscopi
ctg
assay
initi
screen
identifi
four
compound
obatoclax
emetin
niclosamid
ganciclovir
nonecytotox
concentr
rescu
cell
virusmedi
death
figur
determin
effici
toxic
inhibitor
measur
viabil
mock
virusinfect
cell
h
use
ctg
assay
figur
si
obatoclax
emetin
niclosamid
ganciclovir
respect
tabl
titrat
produc
drugtreat
nontreat
cell
cell
figur
experi
reveal
obatoclax
emetin
niclosamid
ganciclovir
lower
product
rpe
cell
thu
identifi
novel
activ
obatoclax
emetin
niclosamid
confirm
known
activ
ganciclovir
similarli
examin
bsaa
wildtyp
rpe
cell
monitor
viabil
mock
virusinfect
cell
microscopi
ctg
assay
initi
screen
identifi
three
compound
obatoclax
emetin
homoharringtonin
rescu
cell
virusmedi
death
nonecytotox
concentr
determin
effici
toxic
novel
inhibitor
measur
viabil
mock
virusinfect
cell
h
use
ctg
assay
figur
si
obatoclax
emetin
homoharringtonin
respect
tabl
titrat
produc
drugtreat
nontreat
cell
cell
figur
experi
reveal
three
compound
lower
product
confirm
novel
antivir
activ
obatoclax
emetin
homoharringtonin
also
examin
toxic
antivir
activ
bsaa
firefli
luciferas
express
firefli
luciferas
open
read
frame
integr
genom
tzmbl
cell
ltr
promot
primari
screen
identifi
two
compound
brequinar
suramin
suppress
firefli
luciferas
express
without
detect
cytotox
perform
valid
experi
compound
calcul
select
si
brequinar
wherea
si
suramin
figur
tabl
thu
identifi
novel
activ
brequinar
confirm
known
activ
suramin
addit
examin
toxic
antivir
activ
bsaa
rfpexpress
rvfv
rpe
cell
fluoresc
microscopi
ctg
assay
show
obatoclax
emetin
inhibit
rvfvmediat
rfp
express
noncytotox
concentr
figur
si
obatoclax
si
emetin
tabl
next
test
bsaa
gfpexpress
hmpv
hmpvmediat
gfp
express
cell
viabil
measur
h
initi
screen
identifi
two
compound
obatoclax
emetin
lower
gfp
express
without
detect
cytotox
replic
experi
confirm
hit
figur
si
obatoclax
six
emetin
tabl
next
test
bsaa
gfpexpress
fluav
rpe
cell
initi
screen
identifi
two
compound
obatoclax
emetin
lower
gfp
express
without
detect
cytotox
repeat
experi
compound
confirm
initi
hit
figur
si
obatoclax
emetin
tabl
thu
identifi
novel
antifluav
activ
emetin
confirm
known
activ
obatoclax
test
whether
obatoclaxemetin
combin
act
synergist
fluavmedi
gfp
express
rescu
infect
cell
death
observ
respons
compar
expect
combin
respons
deviat
observ
expect
respons
show
synergist
effect
figur
e
figur
result
indic
obatoclax
emetin
target
distinct
cellular
pathway
essenti
viru
infect
test
safeinman
bsaa
ssrna
ssrna
rtssrna
dsdna
virus
identifi
novel
activ
five
agent
tabl
figur
identifi
novel
activ
niclosamid
brequinar
homoharringtonin
obatoclax
hmpv
rvfv
emetin
hmpv
rvf
fluav
also
confirm
antivir
activ
ganciclovir
suramin
obatoclax
fluav
result
point
evas
mechan
observ
one
viru
could
relev
virus
exist
bsaa
could
reposit
viral
infect
obatoclax
origin
develop
anticanc
agent
sever
phase
ii
clinic
trial
complet
investig
use
obatoclax
treatment
leukemia
lymphoma
myelofibrosi
mastocytosi
addit
antivir
activ
report
fluav
zikv
wnv
yfv
sinv
junv
lasv
lcmv
vitro
shown
obatoclax
inhibit
viral
endocyt
uptak
target
cellular
induc
myeloid
leukemia
cell
differenti
protein
given
obatoclax
also
inhibit
rvfv
hmpv
could
pursu
potenti
bsaa
candid
emetin
antiprotozo
drug
also
use
induc
vomit
addit
possess
antivir
effect
zikv
ebov
rabv
cmv
propos
emetin
directli
inhibit
viral
polymeras
though
may
target
well
given
emetin
also
inhibit
fluav
rvfv
hmpv
may
repres
promis
bsaa
candid
niclosamid
oral
bioavail
anthelmint
drug
potenti
antineoplast
agent
addit
inhibit
broadest
rang
virus
includ
vitro
case
vivo
shown
niclosamid
induc
endosom
neutral
prevent
viru
entri
host
cell
support
develop
niclosamid
bsaa
homoharringtonin
anticanc
drug
indic
treatment
chronic
myeloid
leukemia
also
possess
antivir
activ
hbv
merscov
vzv
homoharringtonin
bind
ribosom
inhibit
viral
protein
synthesi
interf
chain
elong
given
homoharringtonin
also
inhibit
may
repres
promis
bsaa
candid
brequinar
investig
anticanc
agent
phase
iii
brequinar
attenu
replic
denv
wnv
yfv
lasv
junv
lcmv
vsv
powv
inhibit
dihydroorot
dehydrogenas
therebi
block
de
novo
pyrimidin
biosynthesi
essenti
transcript
replic
viral
rna
given
brequinar
also
inhibit
may
repres
promis
bsaa
candid
human
nonmalign
rpe
cell
line
repres
excel
model
system
studi
infect
differ
virus
addit
differ
viral
strain
express
report
protein
rvfvrfp
hmpvgfp
fluavgfp
excel
tool
drug
screen
howev
number
novel
confirm
antivir
activ
bsa
could
higher
use
cell
line
viral
strain
differ
viru
load
differ
measur
endpoint
differ
time
compound
addit
well
higher
puriti
concentr
rang
bsaa
moreov
antivir
properti
bsaa
detect
celllinebas
assay
might
reproduc
vivo
system
mechan
may
compens
block
target
effect
thu
followup
studi
need
valid
initi
hit
altogeth
expand
spectrum
antivir
action
niclosamid
brequinar
homoharringtonin
obatoclax
emetin
vitro
importantli
pk
safeti
studi
perform
compound
laboratori
anim
human
inform
could
use
initi
efficaci
studi
vivo
save
time
resourc
effect
toler
bsaa
combin
global
impact
improv
prepared
protect
gener
popul
emerg
reemerg
viral
threat
rapid
manag
drugresist
strain
well
use
firstlin
treatment
prophylaxi
viral
coinfect
bsaa
could
pivot
role
battl
emerg
reemerg
viral
diseas
develop
novel
bsaa
could
save
time
resourc
requir
develop
drug
vaccin
futur
bsaa
could
global
impact
decreas
morbid
mortal
viral
diseas
maxim
number
healthi
life
year
improv
qualiti
life
infect
patient
decreas
cost
patient
care
